tirzepatidaes un derivado sintético del polipéptido inhibidor gástrico (GIP) que también tiene funcionalidad simultánea del péptido 1 similar al glucagón (GLP-1). Esta combinación permite que la tirzepatida reduzca los niveles de glucosa en sangre, aumente la sensibilidad a la insulina, aumente la sensación de saciedad y acelere la pérdida de peso. La tirzepatida se desarrolló para combatir la diabetes tipo 2, pero también se ha demostrado que protege el sistema cardiovascular y actúa como un potente agente para perder peso.
Gratis (1) 30 ml de agua bacteriostática con pedidos calificados sobre$500USD.
(excluye productos en cápsulas, péptidos cosméticos, códigos promocionales y envío)
tirzepatidaes un derivado sintético del polipéptido inhibidor gástrico (GIP) que también tiene funcionalidad simultánea del péptido 1 similar al glucagón (GLP-1). Esta combinación permite que la tirzepatida reduzca los niveles de glucosa en sangre, aumente la sensibilidad a la insulina, aumente la sensación de saciedad y acelere la pérdida de peso. La tirzepatida se desarrolló para combatir la diabetes tipo 2, pero también se ha demostrado que protege el sistema cardiovascular y actúa como un potente agente para perder peso.
Uso del producto:Este PRODUCTO ESTÁ DISEÑADO ÚNICAMENTE COMO SUSTANCIA QUÍMICA DE INVESTIGACIÓN.Esta designación permite el uso de productos químicos de investigación estrictamente para pruebas in vitro y experimentación de laboratorio únicamente. Toda la información del producto disponible en este sitio web tiene fines educativos únicamente. La introducción corporal de cualquier tipo en personas o animales está estrictamente prohibida por la ley. Este producto sólo debe ser manipulado por profesionales calificados y con licencia. Este producto no es un medicamento, alimento o cosmético y no puede ser mal etiquetado, mal utilizado o etiquetado erróneamente como medicamento, alimento o cosmético.
tirzepatida
Tirzepatide is a synthetic analogue of gastric inhibitory polypeptide (GIP) that was developed for its ability to stimulate insulin release and thus address both type 2 diabetes and non-alcoholic fatty liver disease. Made up of 39 amino acids, the relatively large Tirzepatide stimulates the release of insulin from the pancreas by binding to both GIP and GLP-1 (glucagon-like peptide-1) receptors. Taken over longer periods of time, Tirzepatide increases adiponectin levels by as much as 26% as well[1]. Research shows that Tirzepatide reduces feelings of hunger, lowers insulin levels, and increases insulin sensitivity. Taken together, these effects cause significant weight loss of 11 kg (25 lbs), improve glucose tolerance, decrease fat (adipose) tissue, and reduce cardiovascular risk.
Estructura de tirzepatida
Secuencia de aminoácidos:YE-Aib-GTFTSDYSI-Aib-LDKIAQ(ácido graso C20)AFVQWLIAGGPSSGAPPPSNota:Aib es un aminoácido no codificado (no proteinógeno) – H2HC(CH)3)2-COOHFórmula molecular:C225h348norte48oh68Peso molecular:4813,527 g/molCID de PubChem:156588324
Número CAS:2023788-19-2Sinónimos:P1206, LY3298176Fuente:PubChem
¿Qué hace la tirzepatida?
Simply put, Tirzepatide increases the release of insulin from the pancreas resulting in improved glucose control. Research shows that, in individuals with Type 2 diabetes, Tirzepatide decreases hemoglobin A1c (HbA1c) levels by 2.4% after six months. The peptide also appears to aid in weight loss, showing a dose-dependent relationship and helping individuals lose as much as 11 kg (25 lbs) over six months[1], [2].
It isn’t just that Tirzepatide increases insulin release though. Research suggests that the peptide actually improves the function of pancreatic beta cells, the cells that make and release insulin. Studies suggest that Tirzepatide may actually make beta cells more effective at processing insulin, which leads not just to increases in insulin levels in the bloodstream, but decreased stress on the beta cells themselves. This may, in turn, help to slow the progressive nature of type 2 diabetes.
Research shows that Tirzepatide doesn’t just increase insulin levels at random though. It appears to do so only in response to increased blood glucose levels. During fasting, Tirzepatide actually decreases insulin levels and thus helps to increase insulin sensitivity over time. It also decreases fasting levels of glucagon, which are thought to exacerbate hyperglycemia by interfering with hepatic glucose metabolism. Overall, these changes are a big part of the reason Tirzepatide has a profound effect on glucose and, ultimately, HbA1c levels[3].
¿Cómo actúa la tirzepatida?
Tirzepatide is a dual agonist of the gastric inhibitory polypeptide receptor and the glucagon-like peptide-1 receptor. Action at these receptors appears to have synergistic effects that make Tirzepatide more effective than strict GLP-1 agonists that are already approved for the treatment of type 2 diabetes. The affinity of Tirzepatide for the GIP receptor is greater than its affinity for the GLP-1 receptor.
Gastric inhibitory polypeptide, which is also referred to as the glucose-dependent insulinotropic polypeptide, is synthesized naturally in the small intestine. This polypeptide binds to the GIP receptor to inhibit gastric acid secretion and gastrin release while stimulating insulin release. The latter is the primary function of GIP-R and is the primary reason that insulin levels increase following a meal.
Glucagon-like peptide-1 receptors are found on beta cells as well as in neurons in the brain. Like GIP-R, stimulation of GLP-1R stimulates the release of insulin. Natural agonists include glucagon and GLP1, but it has also been shown to bind nearly a dozen synthetic agonists including dulaglutide, lithium, and oxyntomodulin. Activation of GLP-1R increases both insulin synthesis and insulin release, factors that have made it a desirable target in drug development. In the brain, GLP-1R stimulation lowers appetite.
Interestingly, stimulation of GLP-1R appears to increase beta cell density in the pancreas. GLP-1R stimulation increases expression of the anti-apoptotic bcl-2 gene while reducing expression of pro-apoptotic bax and caspase-3 genes. This leads to enhanced beta cell survival and, ultimately, to increased levels of insulin[4].
The combination of GIPR and GLP-1R activity is what gives Tirzepatide an edge over strict GLP-1R agonists. Research shows that Tirzepatide acts identically to GIP at the GIPR, but favors cAMP production over β-arrestin recruitment when acting at the GLP-1R. These details may seem esoteric to some extent, but this difference in activity from endogenous GLP-1 appears to cause GLP-1R activation without increasing physiological internalization of the receptor. The net result is enhanced GLP-1R activity with Tarazepide compared to both endogenous GLP-1 as well as other synthetic GLP-1R agonists[5]. These slight alterations mean that Tirzepatide drastically enhances insulin secretion, promotes feelings of satiety, and reduces inflammation in adipose tissue. These combined effects make it a highly efficacious anti-diabetes peptide.
Finally, Tirzepatide appears to alter adiponectin levels, raising overall levels of the fat-burning peptide. Increased levels of adiponectin reduce fat cell differentiation and increase energy expenditure by making mitochondria more inefficient. A low level of this peptide hormone has been implicated in diseases such as type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease[6]. It is worth noting that elevated adiponectin levels elevate insulin sensitivity, so it would appear that Tirzepatide modulates insulin sensitivity via several mechanisms.
Tirzepatida y el hambre
Research shows that Tirzepatide delays gastric emptying during the earliest phases of its administration but that the effect diminishes over time as a result of tachyphylaxis[7]. These effects are similar to those seen with pure GLP-1R agonists, indicating that this action of Tirzepatide is almost completely controlled by its GLP-1 activity and not at all by its GIP activity.
It appears that the effects of Tirzepatide on gastric emptying can be prolonged if the peptide is taken at a low dose for four weeks and then the dose is escalated. This also helps to mitigate side effects caused by the peptide and creates a veritable win-win for patients. Delayed gastric emptying can help to increase feelings of satiety and reduce hunger as well as food cravings. Combined with the effects Tirzepatide has on glucose levels, this can actually help to alter eating patterns over the long term.
Tirzepatida y peso
As noted above, Tirzepatide use is associated with substantial weight loss over a six-month time interval. A comparison of Tirzepatide to other GLP-1 analogues, like degludoc, indicates a striking difference. Whereas Tirzepatide causes a dose-dependent decrease in weight over time, degludoc and other GLP-1R agonists cause weight gain[12].
It appears that the GIP agonism cause by Tirzepatide is what is responsible for the peptide’s long-term effects on weight. GIP appears to directly impact the insulin-sensitivity of adipocytes, which is likely the mechanism by which Tirzepatide impacts adiponectin levels. In short, Tirzepatide activates GIP receptors in fat cells, which then leads to an increase insulin sensitivity. This, in turn, leads to a reduction in adipose inflammation as well as an increase in adiponectin levels and the associated benefits. This isn’t the whole picture, however.
Research shows that GIP signaling in the central nervous system regulates hypothalamic feeding centers leading to decreased food intake and improved glucose handling. This, in turn, leads to decreased body weight[13]. Thus, it appears that Tirzepatide impacts weight via adiponectin signaling directly in adipose tissue and via CNS alterations that reduce hunger levels via GIPR signaling in the brain.Fuente:Ciencia Directa
Tirzepatida y el corazón
As noted, Tirzepatide alters adiponectin levels. Low adiponectin has been associated with atherosclerosis, obesity, and heart disease while increased adiponectin levels have been associated with decrease risk of all of these things. Research in humans with type 2 diabetes has shown that Tirzepatide improves lipoprotein biomarkers, lowering levels of triglycerides, apoC-III, and a handful of other lipoproteins[8]. Combined, these effects mean reduced risk of heart disease as a likely result of decreased adiposity. Research shows that increased adiponectin levels increase HDL levels while decreasing triglyceride levels, both of which are associated with lower risk of heart disease. The peptide hormone appears to go further though, reducing scavenger receptors in macrophages and increasing the levels of cholesterol efflux to greatly protect against atherosclerosis. Increases in adiponectin levels have been associated with improved nutrition, exercise, and the use of certain lipid-lowering medications[9]. It appears that Tirzepatide has similar beneficial effects.
Research shows that GLP-1 is important in both the direct regulation of cardiovascular risk factors such as hypertension, dyslipidemia, and obesity as well as in the indirect regulation of risk factors like inflammation and endothelial cell dysfunction[10]. The former effects are discussed above and below in relationship to adiponectin. The effects on inflammation and endothelial function, however, appear to be mediated more directly.
In the case of endothelial function, GLP-1 signaling has been shown to induce relaxation of blood vessels leading to decreased blood pressure and enhanced end organ perfusion. This effect appears to result from increased expression of eNOS, the enzyme that generates nitric oxide and induces vascular relaxation. Interestingly, these effects appear to be enhanced in the setting of preexisting cardiovasulcar disease and diabetes[10].
Of course, it is well known that inflammation is directly correlated with atherosclerosis. The details are still being worked out, but GLP-1 signaling appears to decrease inflammation via a handful of mechanisms including reduced NF-κB signaling, decreased MMP-9 activity, inhibited inflammatory cytokine synthesis, and decreases in inflammatory macrophage activity. What is more, these effects appear to last as long as three months after a single dose of a GLP-1R agonist like Tirzepatide[10]. Tirzepatide is undergoing a clinical trial to further evaluate its medium-term effects on individuals with heart failure[11].
Resumen de tirzepatida
La tirzepatida es un derivado sintético del polipéptido inhibidor gástrico (GIP) que también tiene funcionalidad simultánea del péptido 1 similar al glucagón (GLP-1). Esta combinación permite que la tirzepatida reduzca los niveles de glucosa en sangre, aumente la sensibilidad a la insulina, aumente la sensación de saciedad y acelere la pérdida de peso. La tirzepatida se desarrolló para combatir la diabetes tipo 2, pero también se ha demostrado que protege el sistema cardiovascular y actúa como un potente agente para perder peso.
Dr. Kyle Balandrois a Research Advisor in the Endocrine Discovery Division of Lilly Research Laboratories at Eli Lilly and Company in Indianapolis. He received a B.Sc. in biology from Indiana University, a M.Sc. in biotechnology from Northwestern University, and the Ph.D. in molecular biology and biochemistry from Purdue University. Dr. Sloop's research investigates molecular mechanisms that control glucose homeostasis, including insulin secretion and action, with a focus on novel therapeutic targets for metabolic disease. He leads interdisciplinary teams on early drug discovery effort, has formed alliance partnerships with external companies specialized in enabling technologies, and currently has established basic research collaborations with international investigators to explore mechanism of action studies for high value targets, including the areas of GPCR allosterism, ligand bias signaling, and protein-protein interaction. He previously served on the Research Affairs Committee of the Endocrine Society and as faculty for the Society's Early Investigators Workshop and Early Career Forum.
Dr. Kyle Sloop is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
Gurús de péptidosy este doctor. El propósito de la cita del doctor es reconocer, reconocer y acreditar el exhaustivo esfuerzo de investigación y desarrollo realizado por los científicos que estudian este péptido. El Dr. Kyle Sloop figura en[5]y[14]bajo las citas referenciadas.
Citas referenciadas
M. K. Thomaset al., “La tirzepatida, agonista dual de los receptores GIP y GLP-1, mejora la función de las células beta y la sensibilidad a la insulina en la diabetes tipo 2”, J. Clínico. Endocrinol. Metab., vol. 106, núm. 2, págs. 388–396, noviembre de 2020, doi: 10.1210/clinem/dgaa863.
T. Min y S. C. Bain, “El papel de la tirzepatida, el agonista dual de los receptores GIP y GLP-1, en el tratamiento de la diabetes tipo 2: los ensayos clínicos SURPASS”, Diabetes Ther., vol. 12, núm. 1, págs. 143–157, enero de 2021, doi: 10.1007/s13300-020-00981-0.
Frías, Juan Pablo, et al. “Eficacia y tolerabilidad de la tirzepatida, un péptido insulinotrópico dual dependiente de la glucosa y un agonista del receptor del péptido 1 similar al glucagón en pacientes con diabetes tipo 2: un estudio de 12 semanas, aleatorizado, doble ciego y controlado con placebo para evaluar diferentes dosis- Regímenes de escalada”. Diabetes, obesidad y metabolismo, vol. 22, núm. 6, 11 de febrero de 2020, págs. 938–946, 10.1111/dom.13979.
“Resucitando la célula beta en la diabetes tipo 2”, Medscape. http://www.medscape.org/viewarticle/544820 (consultado el 3 de abril de 2022).
F. S. Willardet al., “La tirzepatida es un agonista dual desequilibrado y sesgado de los receptores GIP y GLP-1”, JCI Insight, vol. 5, núm. 17, pág. e140532, doi: 10.1172/jci.insight.140532.
M. L. Hartmanet al., “Efectos de la nueva tirzepatida, agonista dual de los receptores GIP y GLP-1, sobre los biomarcadores de esteatohepatitis no alcohólica en pacientes con diabetes tipo 2”, Diabetes Care. vol. 43, núm. 6, págs. 1352–1355, junio de 2020, doi: 10.2337/dc19-1892.
Urva, Shweta y col. "El nuevo polipéptido insulinotrópico dependiente de glucosa dual y el agonista del receptor del péptido similar al glucagón-1 (GLP-1), tirzepatida, retrasa transitoriamente el vaciamiento gástrico de manera similar a los agonistas selectivos del receptor de GLP-1 de acción prolongada". Diabetes, obesidad y metabolismo, vol. 22, núm. 10, 13 de julio de 2020, págs. 1886–1891, 10.1111/dom.14110.
Wilson, Jonathan M. y otros. "El péptido insulinotrópico dependiente de la glucosa dual y el agonista del receptor del péptido similar al glucagón-1, tirzepatida, mejora los biomarcadores de lipoproteínas asociados con la resistencia a la insulina y el riesgo cardiovascular en pacientes con diabetes tipo 2". Diabetes, obesidad y metabolismo, vol. 22, núm. 12, 15 de septiembre de 2020, págs. 2451–2459, 10.1111/dom.14174.
H. Yanai y H. Yoshida, “Efectos beneficiosos de la adiponectina sobre el metabolismo de la glucosa y los lípidos y la progresión aterosclerótica: mecanismos y perspectivas”, Int. J. Mol. Ciencia, vol. 20, núm. 5, pág. 1190, marzo de 2019, doi: 10.3390/ijms20051190.
M. Tate, A. Chong, E. Robinson, B. D. Green y D. J. Grieve, “Dirección selectiva de la señalización del péptido 1 similar al glucagón como un nuevo enfoque terapéutico para las enfermedades cardiovasculares en la diabetes”, Br. J. Pharmacol., vol. 172, núm. 3, págs. 721–736, febrero de 2015, doi: 10.1111/bph.12943.
UCSD, “Ensayo de obesidad de UCSD: un estudio de tirzepatida (LY3298176) en participantes con insuficiencia cardíaca con fracción de eyección conservada y obesidad (SUMMIT)”. https://clinicaltrials.ucsd.edu/trial/NCT04847557 (consultado el 3 de abril de 2022).
B. Ludviket al., “Tirzepatida una vez a la semana versus insulina degludec una vez al día como complemento a la metformina con o sin inhibidores de SGLT2 en pacientes con diabetes tipo 2 (SURPASS-3): un grupo paralelo, aleatorizado y abierto. , ensayo de fase 3”, Lancet Lond. Inglés, vol. 398, núm. 10300, págs. 583–598, agosto de 2021, doi: 10.1016/S0140-6736(21)01443-4.
Q. Zhang et al., “El polipéptido insulinotrópico dependiente de glucosa (GIP) regula el peso corporal y la ingesta de alimentos a través de la señalización SNC-GIPR”, Cell Metab., vol. 33, núm. 4, págs. 833-844.e5, abril de 2021, doi: 10.1016/j.cmet.2021.01.015.
TODOS LOS ARTÍCULOS E INFORMACIÓN DE PRODUCTOS PROPORCIONADOS EN ESTE SITIO WEB SON SÓLO PARA FINES INFORMATIVOS Y EDUCATIVOS.Los productos ofrecidos en este sitio web se proporcionan únicamente para estudios in vitro. Los estudios in vitro (del latín: en vidrio) se realizan fuera del cuerpo. Estos productos no son medicamentos ni fármacos y no han sido aprobados por la FDA para prevenir, tratar o curar ninguna afección médica, dolencia o enfermedad. La introducción corporal de cualquier tipo en personas o animales está estrictamente prohibida por la ley.
PeptideGurus es un proveedor líder de péptidos de investigación fabricados en Estados Unidos y ofrece productos de alta calidad a precios competitivos. Con un enfoque en la excelencia y el servicio al cliente, garantizan un proceso de pedido seguro y conveniente con envío global.
